PFE heads into its July 28 earnings report with short sellers adding positions at the fastest pace in months, even as the stock drops to its lowest levels of the year.
Short interest is the standout story this week. Bearish positioning has climbed 27% over the past month to 3.5% of the free float — roughly 200 million shares. The move accelerated sharply this week, with shorts up 12% in seven days alone. That pace of accumulation is notable for a mega-cap pharma name. The short score has ticked up to 40.5, its highest reading over the past two weeks, having climbed steadily from 37.5 on June 10. Borrow conditions remain completely loose, with availability running at 2,584% — meaning there are more than 25 shares available to borrow for every one currently lent out. Cost to borrow has edged up 32% on the week to 0.47%, but that remains historically low and does not suggest any squeeze pressure. Shorts face no friction adding here. Options positioning is similarly measured — the put/call ratio at 0.87 sits only fractionally above its 20-day average of 0.86, suggesting no unusual hedging demand beyond the background noise of a stock that has traded defensively all year.
The Street is divided, but the balance of recent analyst sentiment has leaned cautious. RBC Capital upgraded PFE to Sector Perform on June 10, though that merely removes the prior Underperform tag rather than signalling conviction. Morgan Stanley, UBS, and Citi have all maintained neutral-to-equal-weight stances, with targets in the $27–$28 range, while BofA trimmed its target to $26 earlier in the spring. At the bullish end, Guggenheim holds a $36 Buy and HSBC a $32 Buy. The mean analyst target of $29.15 implies around 18% upside from the current $24.72, but the gap between cautious consensus and the stock's continued drift lower tells a story of a name where the bull case has consistently failed to materialise. Valuation is undemanding — a price/earnings multiple near 8.7x and EV/EBITDA around 8.0x — yet the earnings-yield-to-price signal ranks near the bottom third of the universe on momentum. The factor scores are similarly mixed: forward EPS year-on-year uplift ranks in the 97th percentile, and the dividend score is strong at 94, but near-term EPS momentum over 30 and 90 days ranks at just 34 and 43 respectively, reflecting the market's scepticism about execution.
The bull case rests on Pfizer's $60 billion revenue base, a broad prescription drug and vaccine portfolio, and international exposure — particularly emerging markets — that cushions domestic headwinds. The bear case is more immediate: anticipated higher gross-to-net adjustments on Vyndaqel and Ibrance are expected to weigh on reported revenue in the near term, and the market may be underpricing how much those adjustments drag on guidance. The stock has fallen 5% this week and is down roughly 5% over the past month, meaningfully underperforming close peer BMY, which slipped just 1.3% on the week, and AZN, which actually gained 3% over the same period.
The insider picture adds little to the bearish thesis but does nothing to counter it. The only trade logged in the past 90 days was the Chief Accounting Officer selling 2,000 shares in early June for around $51,000 — a small, routine transaction. A more telling cluster of executive selling — including CEO Albert Bourla's disposal of over 475,000 shares at roughly $27 in late February — came at prices well above where the stock trades today, suggesting insiders have been trimming into any strength. The top institutional holders, led by BlackRock at 8.7% and State Street at 5.3%, have made only marginal changes to their positions in recent filings, and there is no evidence of a large active manager building a fresh position.
The next major data point is the Q2 earnings release on July 28. After the May print, PFE gained less than 1% on the day before fading to a modest loss over five sessions, and the prior quarter saw a 2% day-one decline. With shorts now at their highest level in months and borrow conditions frictionless, the earnings release is the immediate test of whether that accumulation of bearish positioning reflects genuine conviction or merely tactical hedging ahead of a complex gross-to-net print.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
